BioCentury
ARTICLE | Clinical News

Renova to begin Phase III of RT-100 in heart failure

January 19, 2018 5:39 AM UTC

Renova Therapeutics (San Diego, Calif.) said it will start this quarter the Phase III FLOURISH trial of gene therapy RT-100 (Ad5.hAC6) to treat heart failure with reduced left ventricular ejection fraction (LVEF).

The 12-month, double-blind, placebo-controlled trial will enroll about 536 heart failure patients with LVEF to receive a single intracoronary injection of RT-100 or placebo...

BCIQ Company Profiles

Renova Therapeutics